César Milstein

Last updated

César Milstein
Milstein lnp restauracion.jpg
Born(1927-10-08)8 October 1927
Bahía Blanca, Argentina
Died24 March 2002(2002-03-24) (aged 74)
Cambridge, England
Nationality Argentine, naturalised as British
Alma mater
Known forReceiving Nobel Prize "for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies"
Spouse
Celia Prilleltensky
(m. 1953)
[1]
Awards
Scientific career
Fields Biochemistry
Doctoral advisor Andrés O.M. Stoppani [3]

(1928-2020)

César Milstein, CH, FRS [2] (8 October 1927 – 24 March 2002) was an Argentine biochemist in the field of antibody research. [4] [5] [6] [7] [8] Milstein shared the Nobel Prize in Physiology or Medicine in 1984 with Niels Kaj Jerne and Georges J. F. Köhler for developing the hybridoma technique for the production of monoclonal antibodies. [9] [10] [11] [12] [3] [13] [14]

Contents

Biography

Milstein was born in Bahía Blanca, Argentina. His parents were Máxima (Vanarks) and Lázaro Milstein, a Jewish Ukrainians Jewish Ukrainian immigrant. [15] He graduated from the University of Buenos Aires and obtained a PhD under Professor Stopani [16] (Professor of Biochemistry). Later he became a member of the Medical Research Council Laboratory of Molecular Biology, Cambridge, England; he acquired British citizenship and had dual British-Argentinian nationality. [17] In 1956, he received an award from the Sociedad Argentina de Investigation eon Bio Quimica (SAIB) for his work on enzyme kinetics kinetic studies with the enzyme aldehyde dehydrogenase. In 1958, funded by the British Council, he joined the Biochemistry Department at the University of Cambridge to work for a PhD under Malcolm Dixon on the mechanism of metal activation of the enzyme phosphoglucomutase. [18] During this work, he collaborated with Frederick Sanger, whose group he joined with a short-term Medical Research Council appointment.

Career

Science will only fulfill its promises when the benefits are equally shared by the really poor of the world

César Milstein

The major part of Milstein's research career was devoted to studying the structure of antibodies and the mechanism by which antibody diversity is generated. It was as part of this quest that, in 1975, he worked with Georges Köhler (a postdoctoral fellow in his laboratory) to develop the hybridoma technique for the production of monoclonal antibodies—a discovery recognized by the award of the 1984 Nobel Prize for Physiology or Medicine. This discovery led to an enormous expansion in the exploitation of antibodies in science and medicine. The term hybridoma was coined by Leonard Herzenberg during his sabbatical in Milstein's laboratory between 1976 and 1977. [19]

Milstein himself made many major contributions to improvements and developments in monoclonal antibody technology—especially in the use of monoclonal antibodies to provide markers that allow distinction between different cell types. In collaboration with Claudio Cuello, he helped lay the foundation for the use of monoclonal antibodies as probes for the investigation of the pathological pathways in neurological disorders as well as many other diseases. [20] Milstein and Cuello's work also enabled the use of monoclonal antibodies to enhance the power of immuno-based diagnostic tests. [21] In addition, Milstein foresaw the potential wealth of ligand-binding reagents that could result from applying recombinant DNA technology to monoclonal antibodies and inspired the development of the field of antibody engineering, which was to lead to safer and more powerful monoclonal antibodies for use as therapeutics.

Milstein's early work on antibodies focused on their diversity at the amino acid level, as well as on the disulfide bonds by which they were held together. Part of this work was done in collaboration with his wife, Celia. The emphasis of his research then shifted towards the mRNA encoding antibodies, where he was able to provide the first evidence for the existence of a precursor for these secreted polypeptides that contained a signal sequence. [22] The development of the hybridoma technology coupled to advances in nucleic acid sequencing allowed Milstein to chart the changes that occurred in antibodies following antigen encounter. He demonstrated the importance of somatic hypermutation of immunoglobulin V genes in antibody affinity maturation. In this process, localized mutation of the immunoglobulin genes allows the production of improved antibodies, which make a major contribution to protective immunity and immunological memory. Much of his work in later years was devoted to characterizing this mutational process with a view to understanding its mechanism. He contributed a manuscript [23] for publication on this topic less than a week before he died.

Quite apart from his own achievements, Milstein acted as a guide and inspiration to many in the antibody field, as well as devoting himself to assisting science and scientists in less developed countries. Milstein patented the production of monoclonal antibodies, [24] and held three other patents.

Awards and honours

In addition to the Nobel Prize in 1984, Milstein was elected a Fellow of the Royal Society (FRS) in 1975, [2] was a fellow of Darwin College, Cambridge, from 1980 to 2002, awarded the Louisa Gross Horwitz Prize from Columbia University in 1980, won the Copley Medal in 1989, and became a Member of the Order of the Companions of Honour in 1995. In 1993, the Argentinian Konex Foundation granted him the Diamond Konex Award, one of the most prestigious cultural awards of Argentina, as the most important scientist in the last decade of his country.

Personal life

Milstein married Celia Prilleltensky in 1953.

Milstein died early on 24 March 2002, in Cambridge, England, at age 74, as a result of a heart condition that he had suffered from for many years. [25] [26] [27] [28] [29] His wife died in 2020 aged 92.

The film "Un fueguito, la historia de César Milstein" was released in 2010. Directed by Ana Fraile, the film was awarded Best Documentary by the Academy of Film in Argentina.

See also

Related Research Articles

<span class="mw-page-title-main">Monoclonal antibody</span> Antibodies from clones of the same blood cell

A monoclonal antibody is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.

<span class="mw-page-title-main">Niels Kaj Jerne</span> Danish immunologist (1911–1994)

Niels Kaj Jerne, FRS was a Danish immunologist. He shared the Nobel Prize in Physiology or Medicine in 1984 with Georges J. F. Köhler and César Milstein "for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies".

In immunology, antiserum is a blood serum containing antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

<span class="mw-page-title-main">Hybridoma technology</span> Method for producing lots of identical antibodies

Hybridoma technology is a method for producing large numbers of identical antibodies. This process starts by injecting a mouse with an antigen that provokes an immune response. A type of white blood cell, the B cell, produces antibodies that bind to the injected antigen. These antibody producing B-cells are then harvested from the mouse and, in turn, fused with immortal myeloma cancer cells, to produce a hybrid cell line called a hybridoma, which has both the antibody-producing ability of the B-cell and the longevity and reproductivity of the myeloma. The hybridomas can be grown in culture, each culture starting with one viable hybridoma cell, producing cultures each of which consists of genetically identical hybridomas which produce one antibody per culture (monoclonal) rather than mixtures of different antibodies (polyclonal). The myeloma cell line that is used in this process is selected for its ability to grow in tissue culture and for an absence of antibody synthesis. In contrast to polyclonal antibodies, which are mixtures of many different antibody molecules, the monoclonal antibodies produced by each hybridoma line are all chemically identical.

<span class="mw-page-title-main">Georges J. F. Köhler</span> German biologist (1946–1995)

Georges Jean Franz Köhler was a German biologist.

<span class="mw-page-title-main">Gregory Winter</span> English biochemist (born 1951)

Sir Gregory Paul Winter is a Nobel Prize-winning English molecular biologist best known for his work on the therapeutic use of monoclonal antibodies. His research career has been based almost entirely at the MRC Laboratory of Molecular Biology and the MRC Centre for Protein Engineering, in Cambridge, England.

<span class="mw-page-title-main">Clonal selection</span> Model of the immune system response to infection

In immunology, clonal selection theory explains the functions of cells of the immune system (lymphocytes) in response to specific antigens invading the body. The concept was introduced by Australian doctor Frank Macfarlane Burnet in 1957, in an attempt to explain the great diversity of antibodies formed during initiation of the immune response. The theory has become the widely accepted model for how the human immune system responds to infection and how certain types of B and T lymphocytes are selected for destruction of specific antigens.

<span class="mw-page-title-main">HAT medium</span>

HAT Medium is a selection medium for mammalian cell culture, which relies on the combination of aminopterin, a drug that acts as a powerful folate metabolism inhibitor by inhibiting dihydrofolate reductase, with hypoxanthine and thymidine which are intermediates in DNA synthesis. The trick is that aminopterin blocks DNA de novo synthesis, which is absolutely required for cell division to proceed, but hypoxanthine and thymidine provide cells with the raw material to evade the blockage, provided that they have the right enzymes, which means having functioning copies of the genes that encode them.

<span class="mw-page-title-main">MRC Laboratory of Molecular Biology</span> Research institute in Cambridge, England

The Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) is a research institute in Cambridge, England, involved in the revolution in molecular biology which occurred in the 1950–60s. Since then it has remained a major medical research laboratory at the forefront of scientific discovery, dedicated to improving the understanding of key biological processes at atomic, molecular and cellular levels using multidisciplinary methods, with a focus on using this knowledge to address key issues in human health.

The following are notable events in the Timeline of immunology:

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

<span class="mw-page-title-main">Monoclonal antibody therapy</span> Form of immunotherapy

Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.

<span class="mw-page-title-main">Idiotype</span>

In immunology, an idiotype is a shared characteristic between a group of immunoglobulin or T-cell receptor (TCR) molecules based upon the antigen binding specificity and therefore structure of their variable region. The variable region of antigen receptors of T cells (TCRs) and B cells (immunoglobulins) contain complementarity-determining regions (CDRs) with unique amino acid sequences. They define the surface and properties of the variable region, determining the antigen specificity and therefore the idiotope of the molecule. Immunoglobulins or TCRs with a shared idiotope are the same idiotype. Antibody idiotype is determined by:

<span class="mw-page-title-main">Brigitte Askonas</span> British immunologist (1923–2013)

Brigitte Alice Askonas was a British immunologist and a visiting professor at Imperial College London from 1995.

A rabbit hybridoma is a hybrid cell line formed by the fusion of an antibody producing rabbit B cell with a cancerous B-cell (myeloma).

Jerrold Schwaber was an American biologist and geneticist. In 1973 he described, with Edward Cohen, a method of producing antibodies involving human–mouse hybrid cells, or hybridomas. They fused "mouse myeloma cells secreting immunoglobulin of known specificity and human peripheral blood lymphocytes not secreting detectable immunoglobulin. The hybrid cells continued secretion of mouse immunoglobulin and initiate synthesis and secretion of human immunoglobulin." The antibody producing cells did not survive long and the antigens that the antibodies targeted remained unknown. In 1975, Georges Köhler, César Milstein, and Niels Kaj Jerne, succeeded in making hybridomas that made antibodies to known antigens and that were immortalized. They shared the Nobel Prize in Physiology or Medicine in 1984 for the discovery. His work in laying the foundation for modern monoclonal antibody technology is recognized.

Elizabeth Marian Press was a British immunologist, best known for her work with Rodney Porter on the structure of antibodies. She worked side by side with Porter for 25 years, at the National Institute for Medical Research, St Mary's Hospital and in the Medical Research Council Immunochemistry Unit, and played a major role in him being awarded the Nobel Prize in 1972.

Recombinant antibodies are antibody fragments produced by using recombinant antibody coding genes. They mostly consist of a heavy and light chain of the variable region of immunoglobulin. Recombinant antibodies have many advantages in both medical and research applications, which make them a popular subject of exploration and new production against specific targets. The most commonly used form is the single chain variable fragment (scFv), which has shown the most promising traits exploitable in human medicine and research. In contrast to monoclonal antibodies produced by hybridoma technology, which may lose the capacity to produce the desired antibody over time or the antibody may undergo unwanted changes, which affect its functionality, recombinant antibodies produced in phage display maintain high standard of specificity and low immunogenicity.

<span class="mw-page-title-main">Terry Pearson (immunologist)</span> Canadian biochemist, immunologist, educator and biotechnology entrepreneur

Terry William Pearson is a Canadian biochemist, immunologist, educator and biotechnology entrepreneur.

References

  1. "Michael Clark, Obituary César Milstein (1927–2002), biochemist.org" (PDF). Archived from the original (PDF) on 23 September 2015. Retrieved 11 February 2013.
  2. 1 2 3 Neuberger, M. S.; Askonas, B. A. (2005). "Cesar Milstein CH. 8 October 1927 – 24 March 2002: Elected F.R.S. 1974". Biographical Memoirs of Fellows of the Royal Society . 51: 267–289. doi:10.1098/rsbm.2005.0017.
  3. 1 2 César Milstein on Nobelprize.org OOjs UI icon edit-ltr-progressive.svg
  4. Horenstein, A. L.; Ferrero, E.; Funaro, A.; Crivellin, F.; Said, M. (2002). "César Milstein, scientist (1927–2002)". Journal of Biological Regulators and Homeostatic Agents. 16 (1): 91–92. PMID   12425336.
  5. Springer, Timothy A (June 2002). "César Milstein, the father of modern immunology". Nature Immunology . 3 (6): 501–3. doi:10.1038/ni0602-501. PMID   12032559. S2CID   29375124.
  6. Springer, Timothy A (May 2002). "Immunology. Retrospective: César Milstein (1927–2002)". Science . 296 (5571): 1253. doi:10.1126/science.1073325. PMID   12016298. S2CID   161691240.
  7. Neuberger, Michael (April 2002). "César Milstein (1927-2002)". Current Biology . 12 (9): R308–10. doi: 10.1016/S0960-9822(02)00823-0 . PMID   12007427. S2CID   5279668.
  8. Rajewsky, Klaus (April 2002). "Obituary: César Milstein (1927-2002)". Nature . 416 (6883): 806. Bibcode:2002Natur.416..806R. doi: 10.1038/416806a . PMID   11976669.
  9. Raju, T N (January 2000). "The Nobel chronicles. 1984: Niels Kai Jerne, (1911–94); César Milstein (b 1926); and Georges Jean Franz Köhler (1946–95)". The Lancet . 355 (9197): 75. doi:10.1016/S0140-6736(05)72025-0. PMID   10615922. S2CID   54392404.
  10. Bolhuis, R L; Haaijman J J (December 1984). "[Nobel Prizes for immunology 1984 (Niels K. Jerne, Cesar Milstein, George Köhler)]". Nederlands Tijdschrift voor Geneeskunde . 128 (52): 2433–5. PMID   6395024.
  11. Kaartinen, M. (1984). "The 1984 Nobel Prize in medicine (Cesar Milstein, George Köhler, Niels Jerne)". Duodecim; Laaketieteellinen Aikakauskirja. 100 (23–24): 1573–1578. PMID   6394268.
  12. Onneby, M. (1984). "Immunology in theory and practice. Nils K Jerne shares the Nobel prize in medicine with Georges JF Köhler and Cesar Milstein". Nordisk Medicin. 99 (11): 300, 304. PMID   6393048.
  13. The Story of César Milstein and Monoclonal Antibodies Archived 7 June 2013 at the Wayback Machine on WhatisBiotechnology.org Archived 19 June 2019 at the Wayback Machine
  14. The Papers of César Milstein Archived 5 November 2021 at the Wayback Machine – Churchill Archives Centre
  15. "conjoined a Nuestros Cientificos" [Meeting our Scientists] (in Spanish). Archived from the original on 27 February 2014. Retrieved 9 December 2015.
  16. Stopani, A. O. M.; Milstein, C. (1957). "Essential role of thiol groups in aldehyde dehydrogenases". The Biochemical Journal. 67 (3): 406–416. doi:10.1042/bj0670406. PMC   1200171 . PMID   13479397.
  17. "César Milstein | Argentine immunologist". Encyclopedia Britannica. Archived from the original on 22 March 2019. Retrieved 17 October 2018.
  18. Milstein, C. (1961). "Inhibition of phosphoglucomutase by trace metals". Biochem. J. 79 (3): 591–596. doi:10.1042/bj0790591. PMC   1205690 . PMID   13771002.
  19. Milstein, César (11 October 1999). "The hybridoma revolution: an offshoot of basic research". BioEssays. 21 (11): 966–973. doi:10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z. PMID   10517870. The term hybridoma was proposed by Len Herzenberg during a sabbatical in my laboratory in 1976/1977. At a high-table conversation at a Cambridge College, Len was told by one of the dons that hybridoma was garbled Greek. By then, however, the term was becoming popular among us, and we decided to stick to it.
  20. Cuello, A. C.; Galfre, G.; Milstein, C. (1979). "Detection of substance-P in the central nervous system by a monoclonal antibody". Proc. Natl. Acad. Sci. USA. 76 (7): 3532–3536<<<. Bibcode:1979PNAS...76.3532C. doi: 10.1073/pnas.76.7.3532 . PMC   383862 . PMID   386341.
  21. The Story of César Milstein and Monoclonal Antibodies Archived 1 October 2013 at the Wayback Machine .
  22. Milstein, C.; Clegg, J. B.; Jarvis, J. M. (1967). "C-Terminal half of immunoglobulin λ chains". Nature. 214 (5085): 270–272. Bibcode:1967Natur.214..270M. doi:10.1038/214270a0. PMID   4166495. S2CID   4144338.
  23. Rada, C.; Jarvis, J. M.; Milstein, C. (2002). "AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization". Proc. Natl. Acad. Sci. USA. 99 (10): 7003–7008. Bibcode:2002PNAS...99.7003R. doi: 10.1073/pnas.092160999 . PMC   124518 . PMID   12011459.
  24. espacenet, patents (n.d.). "production of monoclonal antibodies". Archived from the original on 15 March 2024. Retrieved 1 October 2023.
  25. "The Nobel Prize in Physiology or Medicine 1984". NobelPrize.org. Archived from the original on 10 May 2022. Retrieved 10 December 2021.
  26. "César Milstein | Argentine immunologist | Britannica". www.britannica.com. Archived from the original on 22 March 2019. Retrieved 10 December 2021.
  27. "Obituary: César Milstein". the Guardian. 27 March 2002. Archived from the original on 1 May 2022. Retrieved 10 December 2021.
  28. "Cesar Milstein". www.jewishvirtuallibrary.org. Archived from the original on 10 December 2021. Retrieved 10 December 2021.
  29. "Nobel-Winning Biologist Cesar Milstein Dies at 74". The Washington Post . Archived from the original on 15 March 2024. Retrieved 10 December 2021.